Consun Pharmaceutical Group Limited (FRA:C1P)

Market Cap	1.44B
Revenue (ttm)	388.35M
Net Income (ttm)	119.93M
Shares Out	n/a
EPS (ttm)	0.14
PE Ratio	11.97
Forward PE	10.37
Dividend	0.07 (4.88%)
Ex-Dividend Date	Sep 4, 2025

Volume	n/a
Average Volume	1,302
Open	1.600
Previous Close	1.600
Day's Range	1.600 - 1.600
52-Week Range	0.590 - 1.600
Beta	n/a
RSI	74.49
Earnings Date	Aug 22, 2025

About FRA:C1P

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 3,164
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C1P

Financial Performance

In 2024, FRA:C1P's revenue was 2.97 billion, an increase of 14.56% compared to the previous year's 2.59 billion. Earnings were 910.46 million, an increase of 16.05%.

Financial numbers in CNY